# Ultralow Dose PET Imaging of 18F-flurpiridaz

Study · id `cardio:ct-nct07284576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07284576](<https://clinicaltrials.gov/study/NCT07284576>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07284576

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07284576. Allocation not applicable; no masking; primary purpose diagnostic. Start 2025-12-16 (actual); primary completion 2030-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07284576, source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)
- Started: 2025-12-16 (actual) (ClinicalTrials.gov record NCT07284576, source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT07284576, source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)
- Completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT07284576, source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07284576, source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07284576-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ultralow Dose PET Imaging of 18F-flurpiridaz
- Condition: Healthy Volunteer
- Condition: Coronary Arterial Disease
- Condition: Myocardial Ischemia
- Condition: Myocardial Infarction
- Intervention (Drug): 18F-flurpiridaz
- Lead sponsor: Akiva Mintz
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: 95eeaa8c6dc7597132f68a7b5a0588b385e79bdc97f90bd09b8c50f5cfea7db5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
